Biogen Inc. (BIIB) has a MoatMap StockRank of 98/100 based on Quality (65/100), Value (56/100), and Momentum (74/100) factor scores. The current signal is STRONG BUY. Biogen, as a major biotech player focused on neurology, aligns with the 'Specialty Pharma & Biotech Growth' theme. However, its mediocre quality score of 50 and historical challenges with drug approvals and commercialization raise concerns about its ability to be a true quality compounder or deliver asymmetric returns.
Biogen Inc. is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. The company holds a leading market position in multiple sclerosis treatments and is a pioneer in Alzheimer's disease research, backed by a robust R&D pipeline. Its specialized focus on neuroscience provides a distinct competitive advantage and addresses significant unmet medical needs.
| Price | $193.76 |
| Market Cap | $28.6B |
| P/E (TTM) | 20.49 |
| P/E (Forward) | 11.48 |
| Price/Book | 1.51 |
| Return on Equity | 7.7% |
| Return on Invested Capital | 7.0% |
| Debt/Equity | 35.18 |
| Gross Margin | 78.7% |
| Operating Margin | 22.9% |
| Revenue Growth | 1.9% |
| Free Cash Flow | $1.9B |
Biogen Inc. operates in the Drug Manufacturers - General industry, part of the Healthcare sector (United States).